Skip to main content
Premium Trial:

Request an Annual Quote

Flatiron Health, Japanese Hospital Partner on Real-World GI Cancer Database

NEW YORK – Flatiron Health said Wednesday that it is teaming with the National Cancer Center Hospital East in Japan to build a real-world database of patients with gastrointestinal cancers.

New York-based Flatiron will work with the hospital through the company's Flatiron Health K.K. subsidiary in Japan to curate aggregated and de-identified data from consented GI cancer patients and build datasets to support both research and treatment. The datasets will be available for NCCHE clinicians as well as for outside researchers and regulatory decision-makers, according to Roche-owned Flatiron.

NCCHE and Flatiron will also make the data available through SCRUM-Japan, the Cancer Genome Screening Project for Individualized Medicine in that country. NCCHE is a member of that consortium of business and academic organizations.

This deal is part of a new companywide strategy at Flatiron to work through international subsidiaries in the UK, Germany, and Japan to partner with hospitals and healthcare networks in those countries to improve the quality of research and clinical data.

"This agreement marks a major milestone in our commitment to bring Flatiron's real-world data expertise into partnerships with hospitals and health networks in Asia and Europe," Flatiron CEO Carolyn Starrett said in a statement. "Adding more patient experiences into the evidence that supports treatment, development, and regulatory decisions is the best hope for truly transforming global cancer research and care."

The Scan

Call for a Different Tack

Experts weigh the value of recent experiments testing genetically modified pig kidneys using brain-dead individuals, according to Nature News.

Wastewater Warning

The New York Times reports that wastewater surveillance in some parts of the US point to a possible surge.

Can't Get in the Program

Due to the Northern Ireland protocol dispute, the European Union is preventing UK researchers from joining the Horizon Europe research program, the Times of London reports.

Science Paper on Spatial-Controlled Genome Editing

In Science this week: approach to enable a CRISPR-Cas13a-based system to be used as a cancer therapy.